Free Trial
NASDAQ:MGTX

MeiraGTx Q1 2023 Earnings Report

MeiraGTx logo
$8.67 +0.10 (+1.17%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$8.68 +0.01 (+0.12%)
As of 07/16/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MeiraGTx EPS Results

Actual EPS
-$0.62
Consensus EPS
-$0.65
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

MeiraGTx Revenue Results

Actual Revenue
$3.33 million
Expected Revenue
$7.73 million
Beat/Miss
Missed by -$4.40 million
YoY Revenue Growth
N/A

MeiraGTx Announcement Details

Quarter
Q1 2023
Time
N/A
Conference Call Date
Thursday, May 11, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

MeiraGTx's Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled on Tuesday, August 12, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

MeiraGTx Earnings Headlines

Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.
MeiraGTx Holdings plc (MGTX) - Yahoo Finance
See More MeiraGTx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MeiraGTx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MeiraGTx and other key companies, straight to your email.

About MeiraGTx

MeiraGTx (NASDAQ:MGTX) is a clinical-stage gene therapy company dedicated to discovering, developing and commercializing novel treatments for patients with severe inherited and acquired diseases. The company’s expertise spans vector design, novel gene therapy constructs and scalable manufacturing, with the goal of delivering durable, one-time treatments that address the underlying genetic causes of disease rather than merely managing symptoms.

The company’s pipeline includes programs in ophthalmology, targeting inherited retinal diseases such as retinitis pigmentosa and Leber congenital amaurosis, as well as regenerative medicine and neuroscience indications. In addition to its vision-focused candidates, MeiraGTx is advancing gene therapy approaches for chronic pain and gastrointestinal disorders. These programs leverage both adeno-associated virus (AAV) platforms and mRNA delivery technologies to achieve sustained therapeutic benefit.

Headquartered in London, U.K., and Cambridge, Massachusetts, MeiraGTx operates cGMP-compliant manufacturing facilities in both regions, supporting both early-stage research and late-stage clinical production. The company was founded in 2015 and began trading publicly on the NASDAQ stock exchange under the symbol MGTX in 2019. MeiraGTx collaborates with academic institutions and clinical centers around the world to conduct its trials and expand access to its investigational therapies.

View MeiraGTx Profile

More Earnings Resources from MarketBeat